Resources

Search results

• Table. Combination hepatitis A-hepatitis B vaccines

  27 September 2021

  Table

  Number of doses and recommended dosage fo combination hepatitis A-hepatitis B vaccines by age of vaccine recipient.

  

• Table. Common side effects following immunisation for vaccines used in the National Immunisation Program schedule

  18 January 2025

  Table

  Common adverse events following immunisation (AEFI) are usually mild and temporary. They usually occur in the first few days after vaccination. Specific treatment is not usually needed.

  

• Table. Comparison of the effects of diseases and the side effects of vaccines on the National Immunisation Program

  18 January 2025

  Table

  Table showing the diseases on the National Immunisation Program, effects of these diseases and the side effects of vaccines.

  

• Table. Completing rabies post-exposure prophylaxis in Australia that started overseas

  9 October 2024

  Table

  Completing post-exposure prophylaxis in Australia that started overseas based on possible scenarios.

  

• Table. Components of immunisation products used in Australia

  2 May 2025

  Table

  Various components of vaccines used in Australia

  

• Table. Conditions associated with increased risk of severe RSV disease in adults

  17 January 2025

  Table

  Adults aged ≥60 years with the medical conditions listed below are at increased risk of severe RSV disease and are recommended to receive RSV vaccine.

  

• Table. Contact information for notifying adverse events following immunisation

  1 February 2024

  Table

  Key Australian state or territory contacts and resources for notifying adverse events following immunisation.

  

• Table. COVID-19 vaccine primary and further dose recommendations for people with medical conditions that increase their risk of severe illness

  2 May 2025

  Table

  COVID-19 vaccine primary course and further (booster) dose recommendations for people with medical conditions that increase their risk of severe illness, by age group and level of immunocompromise.

  

• Table. Doses of intramuscular 1:1000 adrenaline for anaphylaxis

  30 June 2023

  Table

  Guidance for doses of intramuscular 1:1000 adrenaline for anaphylaxis based on weight in kgs.

  

• Table. Example conditions associated with increased risk of severe outcomes from COVID-19

  2 May 2025

  Table

  This table is not exhaustive and providers may use their judgement to vaccinate people with conditions not listed.

  

• Table. Examples of severely immunocompromising conditions (Ref 10-26) for which additional doses of COVID-19 vaccine are recommended or can be considered

  2 May 2025

  Table

  The example conditions and therapies listed are not exhaustive, and providers may include conditions or therapies similar to those below based on clinical judgement.

  

• Table. Guide to tetanus prophylaxis in wound management

  30 June 2023

  Table

  Guidance for tetanus prophylaxis in wound management based on history of tetanus vaccination, type of wound and time since last dose.

  

• Table. Immunosuppressive potential of biological therapies

  2 May 2025

  Table

  Information on the level of immunosuppressive potential and duration of immunosuppression of biological therapies

  

• Table. Immunosuppressive potential of cancer and organ rejection therapies

  2 May 2025

  Table

  Information on the level of immunosuppressive potential and duration of immunosuppression of different cancer and organ rejection therapies

  

• Table. Immunosuppressive potential of certain medical conditions

  2 May 2025

  Table

  Information on the level of immunosuppressive potential and susceptibility to infectious diseases of certain medical conditions.

  

• Table. Immunosuppressive potential of conventional (non-biological) immunosuppressive therapies

  2 May 2025

  Table

  Information on the level of immunosuppressive potential and duration of immunosuppression of conventional l(non-biological) immunosuppressive therapies.

  

• Table. Immunosuppressive potential of corticosteriods

  2 May 2025

  Table

  Information on the level of immunosuppressive potential and duration of immunosuppression of corticosteroids.

  

• Table. Immunosuppressive potential of small molecule targeted therapies

  2 May 2025

  Table

  Information on the level of immunosuppressive potential and duration of immunosuppression of small molecule targeted therapies.

  

• Table. Interpreting serological and skin test results before Q fever vaccination

  5 June 2018

  Table

  How to interpret serological and skin test results before Q fever vaccination and actions to be undertaken.

  

• Table. Levels of immunocompromise in children and adults with HIV

  2 May 2025

  Table

  Understanding levels of immunocompromise in children and adults with HIV.

  

• Table. Lyssavirus exposure categories

  27 September 2021

  Table

  Various Lyssavirus exposure categories from no exposure to severe exposure, description and recommended post-exposure prophylaxis management.

  

• Table. MenACWY vaccine catch-up for healthy children aged <2 years

  19 July 2024

  Table

  Recommendations for MenACWY catch-up vaccination for healthy children aged <2 years.

  

• Table. MenACWY vaccine primary catch-up for children with specified medical conditions

  19 July 2024

  Table

  Recommendations for primary MenACWY catch-up vaccination for children with specified medical conditions.

  

• Table. MenB vaccine catch-up for children with specified medical conditions

  19 July 2024

  Table

  Recommendations for MenB catch-up vaccination for children with specified medical conditions.

  

• Table. MenB vaccine catch-up for healthy children aged <2 years

  19 July 2024

  Table

  Recommendations for MenB catch-up vaccination for healthy children aged <2 years.